- A Swedish population study shows that low-dose aspirin use is linked to a lower incidence of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B and C.
Why this matters
- Mechanistic studies suggest a protective effect, but observational data in the US and Europe have been flawed.
- Propensity-score-matched analysis from Swedish registries of patients who were prescribed 90 or more doses of low-dose (75 or 160 mg) aspirin (n=50,275).
- Funding: National Institutes of Health; others.
- Median follow-up, 7.9 years.
- Aspirin use was associated with an HCC incidence of 4.0% compared with 8.3% in nonusers:
- Adjusted (a)HR, 0.69 (95% CI, 0.62-0.76).
- Longer use was associated with lower incidence compared with short-term use (3 months to
- 1 to
- 3 to
- ≥5 years: aHR, 0.57 (95% CI, 0.42-0.70).
- 11.0% vs 17.9%;
- aHR, 0.73 (95% CI, 0.67-0.81).
- 7.8% in users vs 6.9% in nonusers;
- Difference, 0.9% (95% CI, −0.6% to 2.4%).
- Retrospective analysis.
- Swedish population.